[Quantitative assessment of protein replacement in therapeutic plasmapheresis].

Aim: To calculate parameters of replacement in which the amount of total protein (TP) in the circulating blood remains above critical level after removal of 17-75% of circulating plasm volume (CPL).

Material And Methods: Therapeutic plasmapheresis (TPA) was made in 96 patients with rheumatoid arthritis, bronchial asthma, systemic lupus erythematosus and other diseases. The plasm was replaced by 0.

[Osmotic activity of plasma in plasmapheresis in patients with multiple myeloma].

Aim: To control safety and efficiency of therapeutic plasmapheresis (PA) by osmolality, colloido-osmotic pressure (COP), total protein concentration before and after the procedure in patients with paraproteinemic hemoblastosis.

Material And Methods: 20 patients with multiple myeloma have undergone 42 PA procedures conducted by two techniques: continuous flow centrifugation on blood fractioners or intermittent centrifugation of blood in plastic containers. The removed plasma volume averaged 1/3 (group 1) or 2/3 of the plasma volume (group 2).

[Reestablishment of plasma proteins after plasmapheresis in patients with paraproteinemic hemoblastosis].

Aim: To study the effect of plasmapheresis (PA) on the changes in plasma total protein in the PA intervals in patients with paraproteinemic hemoblastosis (PPH).

Materials And Methods: 26 PPH patients underwent 80 PA procedures to remove macromolecular pathological proteins and diminish blood viscosity. Before PA the patients were examined hematologically, biochemically.

[The monitoring of protein-volemic indices during plasmapheresis in patients with paraproteinemic hemoblastoses].

We studied quantitative characteristics of plasma protein before, during and after 133 plasmapheresis (PA) procedures in patients with multiple myeloma and Waldenstrom's macroglobulinemia. A value of removed plasma volume (RPV) was calculated as a part plasma volume (PV) before PA with consideration of quantity and consequence of replacement solution. In the case when we removed 30% of calculated PV we replaced it only with electrolyte solutions.

[Therapeutic plasmapheresis in immune complex diseases].

We studied the dependence of the plasma protein and volume on the exfusion volume, type and composition of the substitution solution in 140 plasmapheresis procedures given to patients with immune thrombocytopenic purpura and bronchial asthma. The change of blood protein system corresponded to the procedure regime. The procedure does not entail adverse reactions if it removes up to 30% of the plasma circulating volume (replacement with salt solution), 50% of the plasma circulating volume (replacement with dextran solution) or 95% of that with replacement with albumin.

[Comparative assessment of various programs of plasmapheresis in the combined treatment of patients with rheumatoid arthritis].

Therapeutic efficacy of various plasmapheresis (PA) programmes was comparatively studied in 92 patients with rheumatoid arthritis. PA performed as a placebo (the control group) confirmed the efficacy of PA in the patients with rheumatoid arthritis. The choice of a particular regimen of the procedure depended on the health status of the patient.

[Blood protein-volume indicators in massive plasmapheresis].

Hyperproteinemia values were studied before and after plasmapheresis in 32 rheumatoid arthritis patients with no manifest circulatory disorders. Mathematical patterns enabling prediction of changes in protein concentration depending on the volume of removed plasma and the type of substitution have been proposed for 3 alternative regimens of the procedure (removal of 0.5 or 1.

[Circulating plasma proteins in experimental acute hemorrhage and transfusion of blood components].

In the experiments of dogs reactive changes of proteins in circulation in acute blood loss were studied. With the aim of prevention of homeostasis disorders caused by deficit of plasma proteins, blood protein components should be included into transfusion means.

[Colloid osmotic pressure and the total protein level in assessing the safety of therapeutic plasmapheresis].

In 117 plasmapheresis procedures provided to rheumatic arthritis patients, the authors studied the changes in colloid osmotic pressure (COP), proteinemia and systemic arterial pressure depending on the plasma volume removed and on the type and volume of the substituting solution. Plasmapheresis carried out in 3 alternative regimens was not accompanied by dangerous exchange in the protein system. The substitution of the removed plasma by albumin and rheopolyglukin ensures an effective maintenance of COP just after the procedure.

[Circulating blood plasma proteins during the infusion therapy of blood loss].

Experiments were conducted on 60 dogs to study the total protein level in circulation after acute and prolonged blood loss and infusion of salt and colloid solutions. It was found that the amount of circulating blood in the restorative period depends mainly on the individual initial values and to a lesser degree on the protein loss. A low protein level persists in infusion therapy.

[The protein-blood volume indices during moderate plasmapheresis].

Quantitative characteristics of changes in the volume of circulating plasma and the amount of circulating protein were studied in rheumatoid arthritis patients before and after plasmapheresis of moderate intensity. Basing on the comparison of the precalculated and estimated parameters the authors have suggested 4 mathematical models equally describing the protein-volemic relationships in the body. Satisfactory correlation has been recorded between the estimated and precalculated values of protein concentration in the plasma after plasmapheresis that enables data collection in a short cut program.

[Macroproteinemia and the prognostic assessment of blood loss].

The dependence of blood loss quantitative indices (duration, number and volume of exfusions) on the initial state of the blood protein system was studied in experiments with dogs. The true correlation was found between the macroprotein contents in plasma and the duration of the arterial pressure compensation phase at the level of 5.3 kPa (40 mm Hg).

[Plasma macroproteins in the evaluation of the effectiveness of therapeutic plasmapheresis in patients with rheumatoid arthritis].

In 32 patients with RA before and after lymphocyto- and/or plasmapheresis the authors determined the content of high molecular protein fraction (macroproteins) in the blood plasma. In the consecutive analysis of the body response and procedure effects it was found out that decrease in the level of macroproteins correlated with the changes of immunological status and state of the patients. The index of macroproteinemia can be used for quantitative assessment of plasmacytopheresis effect.

[Mathematical modeling of protein loss during prolonged blood loss].

The dependence of protein losses on the initial condition and experimental conditions were studied in dogs on a model of repeated bloodletting. Various animals have an intensive increase in this value in the beginning and a gradual decrease at later stages. Four mathematical models adequately describing changes in losses depending on the number of bloodlettings and duration of arterial pressure compensation phase have been suggested.

[Hypotensive activity of the plasma proteins in a normovolemic blood exchange transfusion].

The effect of post-hemotransfusion protein fractions on blood pressure, microcirculation and physiologically active substances has been studied in stimulated blood replacement by homologous animal blood. The in vivo and in vitro experiments have revealed that subfraction of hemotransfusion plasma macromolecular proteins has a prominent antihypertensive effect, leading to blood flow slowing in the microvascular bed. Hemotransfusion plasma proteins possess high serotonin-releasing activity.

[Biotesting of a burn toxin on mice with reticuloendothelial system block].

Experiments on mice with reticuloendothelial system blockade were made to assay the toxic properties of the preparations obtained from the skin of burn and normal rats. As regards the activity level the preparations can be classified with either highly toxic or little toxic. Analysis of the dose-response dependence indicates that toxicity of the extracts is accounted for by at least two different toxins.